BIO 4 campus (Biomedicine, Bioinformatics, Biotechnology and Biodiversity) is a project initiated by the government of Serbia, and the ambition of that project is to establish a world-renowned centre for research and development in Serbia, and the campus consists of, among other things, scientific institutes and educational institutions.
The Roche company, which became a partner of the BIO4 campus, will participate in the development of the so-called "precision medicine".
After signing the Memorandum, the Prime Minister said that today is an extremely important day for the further positioning of Serbia on the map of innovation and on the world map of countries that have good capacities for research and development.
The Prime Minister pointed out that in the last few years, Serbia has positioned itself on the European and world map as a country that can contribute to research and innovation in every field, even in traditional industry.
According to her, this year the export of the IT sector will be more than €2.5 billion, with €1.5 billion being our surplus, and this sector currently creates the greatest value in Serbia, which contributes to the further development of the country.
Brnabic noted that for several years already the government has been working with Roche in order to show them that Serbia is a country of innovation, and that part of their research can take place in our country.
We see a trend of more and more foreign companies opening their scientific and research centres in Serbia. In order to continue that trend, we as the government must go further, Brnabic emphasised and added that the two key pillars of our further development are artificial technology and the BIO 4 campus, on which we will start working in 2023.
Treve said that today is the beginning of an extremely important campaign and that a lot of time and effort was invested to make this happen and open the biocentres.
Director of the Institute for Molecular Genetics and Genetic Engineering Jelena Begovic explained that the Memorandum prescribes that work will be done in Serbia on the creation of research and development capacities through research projects, as well as the performance of cancer genomic profiling tests.
She stated that the Memorandum also envisages paving the way for the wider use of precision medicine and the application of individual therapies, i.e., finding the most effective way of treatment for each individual patient.